Tarsus Pharmaceuticals Announces Second Quarter 2025 Sales Growth
Published on August 7, 2025
IRVINE, Calif.—Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a biopharmaceutical company focused on the development and commercialization of therapeutic eyecare treatments, has announced financial results for the second quarter ended June 30, 2025. Net product sales were reported at $102.7 million, compared with $40.8 million for the same period in 2024, driven by approximately 91,000 bottles of Xdemvy delivered to patients compared with approximately 37,000 bottles delivered in the prior-year period. Xdemvy (lotilaner ophthalmic solution) 0.25% is a novel prescription eye drop designed to treat Demodex blepharitis, a condition caused by an overpopulation of Demodex microscopic mites that live in eyelash follicles and meibomian glands. It was approved by the FDA in July of 2023, as reported by VMAIL.